Investigator, Prof Stefan James, Prof Jonas Oldgren (Uppsala University, SE) and Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) discuss the findings of the DAPA-MI trial (NCT04564742).
This multicenter, parallel-group, registry-based, randomized, double-blind and placebo-controlled phase 3 trial (AstraZeneca) investigated the effect of dapagliflozin 10 mg vs placebo, given once daily in addition to standard of care therapy (SoC), on death, hospitalization for HF (HHF) and other cardiometabolic outcomes.
4017 patients were enrolled in the study which excluded participants with known diabetes.
Results presented at AHA 2023 showed that dapagliflozin demonstrated significant benefit in patients with acute MI and impaired left ventricular systolic dysfunction, without diabetes or CHF in regards to improvement in cardiometabolic outcomes as compared to placebo. This effect was consistent across all prespecified subgroups, with no new safety concerns. Clinical event rates were low with no significant difference between randomized groups.
Recorded on-site at AHA Scientific Sessions 2023, Philadelphia.
Support: This is an independent interview produced by Radcliffe Cardiology.
Visit Radcliffe Cardiology: www.radcliffecardiology.com/?...
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: x.com/radcliffeCARDIO
19 ноя 2023
